Skip to main content
Publications
Cheol Lee J, Hung JY, Kim YC, Chang GC, Soo Yoo S, Yang SH, Davis KL , Nagar SP , Taylor A, Yong Lee S, Shih JY. Real-world treatment patterns in patients with EGFR mutation-positive NSCLC receiving a first line, first- or second-generation EGFR tyrosine kinase inhibitor in South Korea and Taiwan . Asian Pac J Cancer Bio. 2021 May 20;6(2). doi: 10.31557/APJCB.2021.6.2.123-132
Saif MW, Parikh R , Ray D, Kaye JA, Kurosky SK, Thomas K, Ramirez RA, Halfdanarson TR, Beveridge TJR, Mirakhur B, Nagar SP , Soares HP. Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors . J Gastrointest Oncol. 2019 Aug;10(4):674-87. doi: 10.21037/jgo.2019.03.11
Herman WH, Hoerger TJ, Hicks K , Brandle M, Sorensen SW, Zhang P, Engelgau MM, Hamman RF, Marrero DG, Ackermann DT, Ratner RE. Managing people at high risk for diabetes . Ann Intern Med. 2006 Jan 3;144(1):66-7.